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Abstract 
The human electroencephalogram (EEG) of sleep undergoes profound changes with age. These changes 
can be conceptualized as “brain age”, which can be compared to an age norm to reflect the deviation 
from normal aging process. Here, we develop an interpretable machine learning model to predict brain 
age based on two large sleep EEG datasets: the Massachusetts General Hospital sleep lab dataset (MGH, 
N = 2,621) covering age 18 to 80; and the Sleep Hearth Health Study (SHHS, N = 3,520) covering age 40 
to 80. The model obtains a mean absolute deviation of 8.1 years between brain age and chronological 
age in the healthy participants in the MGH dataset. As validation, we analyze a subset of SHHS 
containing longitudinal EEGs 5 years apart, which shows a 5.5 years difference in brain age. Participants 
with neurological and psychiatric diseases, as well as diabetes and hypertension medications show an 
older brain age compared to chronological age. The findings raise the prospect of using sleep EEG as a 
biomarker for healthy brain aging. 
 
Introduction 
 
Human sleep undergoes profound changes with age, reflected in both the overall sleep architecture and 
electroencephalogram (EEG) oscillations/waveforms. At the level of sleep architecture (macro-structure), 
older participants tend to sleep earlier and awake earlier; have shorter sleep duration, increased sleep 
fragmentation and reduced percentages of rapid eye movement (REM), as well as (at least in males) 
deep non-REM (NREM) sleep (Mander et al., 2017; Scullin, 2017). At the level of EEG microstructure, 
older participants exhibit reduced slow waves during deep sleep (Carrier et al., 2001; Larsen et al., 
1995), decreased sleep spindle amplitude, density and duration (Purcell et al., 2017), and less phase 
coupling between slow oscillations and sleep spindles (Helfrich et al., 2017). However, no study has yet 
addressed the inverse problem: how accurately can a person’s age be predicted from the sleep EEG? 
What factors make a person’s “brain age” (BA) older or younger than its chronological age (CA)? 
Beyond predicting age from sleep EEG, brain age serves as a potential aging biomarker where variation 
between individuals at the same age may carry important information about the risk of cognitive 
impairment, neurological or psychiatric disease and death. Various biomarkers of aging have been 
proposed to better predict life span and functional capability other than EEG, ranging from molecular 
and cellular level to organ-system level. From the molecular and cellular aspects of aging, related 
biomarkers include leucocyte telomere length (Kruk et al., 1995), Ink4/Arf locus expression 
(Krishnamurthy et al., 2004), N-glycan profile (Vanhooren et al., 2010), mitochondrial DNA deletions 
(Eshaghian et al., 2006), and DNA-methylation status at CpG sites across the genome (Horvath, 2013), 
among others. From the organ-systems level, brain anatomy changes dramatically throughout life (Raz 
and Rodrigue, 2006). For example, cortical volume (Cole, 2017), thalamic volume (Redline et al., 2004), 
and white matter integrity (Mander et al., 2017), each decrease with aging. Using magnetic resonance 
images (MRI), chronological age can be predicted with mean absolute deviation of 5 years in healthy 
participants (Franke et al., 2010). Various diseases, including Alzheimer’s disease, schizophrenia, 
epilepsy, traumatic brain injury, bipolar disorder, major depression, cognitive impairment, diabetes 
mellitus, and HIV, are associated with older brain age than chronological age (Cole et al., 2017; Cole, 
2017; Cole and Franke, 2017; Cole et al., 2016; Franke et al., 2012; Franke et al., 2010). Alongside these 
biomarkers, EEG-based brain age is a sensible potential complement, which has several advantages: (1) 
EEG-based brain age could reflect functional changes rather than anatomical changes; (2) EEG is more 
economical, participant friendly, and in principle could be measured by home-based devices; (3) EEG-
based brain age could facilitate within-participant repeated measures to assess the effectiveness of 
interventions, such as medications (Roehrs and Roth, 2010) or brain stimulation (Tasali et al., 2008) that 
aim to preserve or improve brain function. 
We developed an EEG-based brain age estimate based on two sleep EEG datasets: the Massachusetts 
General Hospital sleep lab (MGH) dataset (Biswal et al., 2017; Sun et al., 2017), and the Sleep Hearth 
Health Study (SHHS) (Dean et al., 2016; Quan et al., 1997; Redline et al., 1998). We identified 
participants with neurological or psychiatric diseases in the MGH dataset, and trained the model only on 
participants without these diseases so that the scatter around the line of identity in testing participants 
is less affected by the clinical heterogeneity in the datasets. The effects of different EEG electrode 
choices were also investigated. The model was then validated on a longitudinal study in the SHHS 
dataset. We correlated the deviation of brain age from chronological age with clinical covariates, 
diseases and medications. Finally, an age norm was derived based on sleep EEG features, using which 
we can interpret the presence of deviations from chronological age. 
 
Material and Methods 
Dataset 
 
The Partners Institutional Review Board approved retrospective analysis of the de-identified 
polysomnograms (PSG) dataset, acquired in MGH between 2008 and 2012, without requiring additional 
consent for its use in this study. The EEG signals contain 6 channels: frontal (F3-M2 and F4-M1), central 
(C3-M2 and C4-M1) and occipital (O1-M2 and O2-M1), each referenced to the contralateral mastoid. 
EEG signals are sampled at 200Hz. The signals are segmented into non-overlapping 30-second epochs. 
There are seven technicians who scored the entire PSGs according to AASM standards (AASM, 2007) 
into one of five stages: wake (W), rapid eye movement (REM), Non-REM stage 1 (N1), Non-REM stage 2 
(N2) and Non-REM stage 3 (N3). Each PSG is scored by one technician. The inclusion criteria include (1) 
age between 18 to 80 years; (2) diagnostic PSG; and (3) with clinical diagnosis not later than one year 
after the PSG recording. We exclude EEGs without all 5 sleep stages. We investigate the effect of 
imputation of missing sleep stages in the supplementary material (Figure S2). 
We define a participant having “neurological or psychiatric disease” as having at least one neurological 
or psychiatric disease in Table S1 in supplementary material, not later than one year after the PSG 
recording. This definition is consistent with the one used in Brain Images of Normal Participants 
(BRAINS) (Job et al., 2017), Open Access Series of Imaging Studies (OASIS) (Marcus et al., 2010), and in 
line with (Steffener et al., 2016) and (Cole et al., 2015). We refer participants without any neurological 
or psychiatric disease as “healthy”. 
In total, we identify 2,621 EEGs where 189 of them have neurological or psychiatric diseases. Table 1 
provides summary statistics for the dataset. 
Table 1. MGH Sleep Dataset Summary 
Characteristics Value: Median (IQR) 
Number of EEGs 
2,621 (including 189 EEGs with 
neurological or psychiatric diseases*) 
Age (year) 50 (37 – 61) 
Gender Female 1,314 (50%), Male 1,307 (50%) 
BMI (kg/m2) 29 (25 – 35) 
Overall AHI (per hour) 5 (2 – 12) 
Normal (<5) 1,273 
Mild sleep apnea (5<=AHI<15) 846 
Moderate sleep apnea (15<=AHI<30) 383 
Severe sleep apnea (AHI>=30) 119 
Medication  
No medication 682 
Systemic 1,493 
Sleep aid 823 
Hypertension 755 
Antidepressant 661 
Neuroactive 509 
Benzodiazepine 465 
RLS/PLMS drugs 242 
Diabetic 211 
Opiate 195 
Antihistamine 151 
Z-drugs 143 
Herbal 126 
Stimulant 121 
Neuroleptic 101 
Legend: IQR: interquartile range; BMI: body mass index; AHI: apnea-hypopnea index (number of apnea 
events per hour of sleep) at 4% oxygen desaturation for hypopnea; *: Refer to Table S1 in the 
supplementary material for the detailed list of diseases that are counted as neurological or psychiatric. 
We also use a subset of the SHHS dataset (Dean et al., 2016; Quan et al., 1997; Redline et al., 1998), 
which contains repeated EEGs from the same participant from two visits about 5 years apart, making it 
possible to evaluate the longitudinal within-participant reliability of our model. Selection criteria are: (1) 
having EEGs from both visits; (2) having a chronological age between 40 to 80 years in both visits 
(minimum age in SHHS is 40); and (3) having EEG and sleep stage scoring of high quality according to 
SHHS specifications. We also exclude EEGs without all 5 sleep stages. As a result, 1,760 EEGs from SHHS 
visit 1 and 1,760 paired EEGs from visit 2 are used. 24 participants have EEGs 4 years apart, 1,294 
participants 5 years apart, 434 participants 6 years apart, and 7 participants 7 years apart. Unlike the 
MGH dataset, the SHHS dataset uses two EEG channels (C3-M2 and C4-M1) and is scored according to 
R&K standard (Rechtschaffen, 1968). To make scoring consistent across datasets, we combine S3 and S4 
in SHHS to match the scoring of N3 in the MGH data. Summary statistics for the SHHS dataset are shown 
in Table 2. 
 
Table 2. Sleep Heart Health Study Dataset Summary 
Characteristics 
SHHS visit 1 (SHHS1) 
Median (IQR) 
SHHS visit 2 (SHHS2) 
Median (IQR) 
Number of EEGs 1,760 
1,760 
(same participants as SHHS1) 
Age (year) 60 (54 – 67) 65 (59 – 73) 
Gender Female 965 (55%), Male 794 (45%) 
BMI (kg/m2) 28 (25 – 31) 28 (25 – 31) 
Overall AHI (per hour) 3 (1 – 9) 6 (2 — 13) 
 
EEG Preprocessing and Artifact Removal 
 
EEG signals are notch-filtered at 60Hz to reduce line noise, and bandpass filtered from 0.5Hz to 20Hz to 
reduce myogenic artifacts. For 30s-epochs, those with absolute amplitude larger than 500uV are 
removed to restrict movement artifacts. Epochs containing flat EEG for more than 2 seconds are also 
removed. To reduce inter-participant variance, the amplitude of each EEG channel is normalized to have 
zero median and unit interquartile range across the whole night. The total amount of data removed by 
these preprocessing procedures is 7% in the MGH dataset and 9% in the SHHS dataset. 
 
Feature Extraction 
 
For brain age prediction, we extracted features from the EEG used for sleep staging in our previous work 
(Sun et al., 2017). We extract 102 features from each 30-second epoch covering both time and 
frequency domains, as summarized in Table S2. For each EEG recording, we average the features in each 
of the 5 sleep stages over time, yielding 102 × 5 = 510 features per EEG. The features are log-
transformed to render the feature distributions approximately Gaussian. Then the features are then z-
transformed to have zero mean and unit standard deviation in the training set, and applied to the 
testing set. 
 
Brain Age Prediction 
 
The model minimizes an objective function        with two terms: (1) the mean squared prediction 
error; and (2) the magnitude of the covariance between    and   (        ): 
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average absolute correlation (covariance) between the chronological age     and brain age deviation 
   . Minimizing the first component of the objective function 〈  
 〉 encourages the model to produce 
predictions BA that are accurate (close to CA). Minimizing the second component            
minimizes systematic prediction error, i.e. encourages deviations of BA from CA to be uncorrelated with 
CA. The second component is weighted by a hyperparameter λ, which is tuned to optimize the tradeoff 
between the two components. 
To determine the optimal hyperparameter λ, we randomly select 300 EEGs from the training set to serve 
as internal validation data. We perform grid search on λ ranging from [0, 1, 5, 10]. We train the model 
on the remaining training EEGs and find the hyperparameter that has the highest performance on the 
internal validation set. The performance metric for each hyperparameter is evaluated using 
                         , where         denotes Pearson’s correlation. A larger             
and a smaller               indicate better model performance. Here the metric is correlation instead 
of covariance or prediction error, since correlation is normalized and comparable among different 
hyperparameter values. Once the optimal hyperparameter with the best validation performance are 
determined, the validation set is combined with the rest of the training set, and the model is re-trained 
using the optimal hyperparameter. 
We maintain strict separation of training and testing data to achieve statistically unbiased estimates of 
model’s performance. The reported results are based on the testing set if not specifically stated. 
 
Results 
Predicting Brain Age from EEG 
 
The MGH dataset is randomly partitioned into a training set (N = 1,343) used to train the model where 
all of them are healthy, and a testing set (N = 1,278) to evaluate model performance among which 189 
have neurological or psychiatric diseases and the rest 1,089 don’t. The comparison between these two 
groups is presented in the later subsection. Here we first compare the age prediction performance 
between using sleep macro-structure features (Mander et al., 2017; Redline et al., 2004) (30 features in 
total, Table S3), and using the 510 sleep micro-structure EEG features, on the testing set. As shown in 
Figure 1, the mean absolute deviation (MAD) of BA from CA using macro-structure features is much 
higher (23.5 years) than that using micro-structure features (8.5 years), and the correlation is weaker 
(0.44, 95% CI 0.40 – 0.48) than that using micro-structure features (0.79, 95% CI 0.77 – 0.81). The results 
suggest that the effects of age on brain activity are more consistently reflected in sleep EEG micro-
structure than in sleep stage composition (macro-structure). The progression of EEG features with age is 
further illustrated by a two-dimensional visualization of the feature space in Figure S1. 
 Figure 1. Scatterplot of predicted BA vs. CA using (A) sleep EEG macro-structure features and (B) sleep 
micro-structure features (Table S3). Both plots are obtained from the same testing participants. The red 
dashed diagonal line is the identity line where BA is equal to CA. The training set contains only healthy 
participants, while the testing set shown here contains participants both with and without neurological 
or psychiatric diseases. 
In Figure 2, we show spectrograms of sleep EEGs from 6 typical individuals, arranged as a “confusion 
matrix”, where rows show participants with CA in young (18 – 30 years), intermediate (40 – 50 years), 
and older adult groups (70 – 80 years) from top to bottom, and columns with BA in three groups from 
left to right. The participants positioned along the diagonal line are examples of participants with 
matched CA and BA in three groups. As an example, the top middle panel indicated by * shows a 25-
year-old female who has been accumulatively diagnosed not later than one year after the study with 
hypertenstive disorder, post-traumatic stress disorder, anxiety, bipolar disorder, dizziness, 
hypercholesterolemia, asthma, irregular periods and. Her EEG shows strong and lasting theta power 
compared to a healthy participant at similar age of 26 (top left), which resembles an older BA at 40s 
(middle column). 
 
Figure 2. Individual cases with BA matches (diagonal) or is younger or older than CA (off diagonal). Each 
panel consists of a hypnogram and the corresponding spectrogram. Spectrograms are calculated as the 
average across the 6 EEG channels. The horizontal axis is time in hours. The case indicated by * is 
described in the main text. 
 
Effect of EEG Electrode Placement 
 
Most home-based EEG devices use fewer electrodes than lab-based PSG. We therefore explore how the 
EEG-based age prediction depends on the number and location of EEG electrodes. The prediction 
performance on the 1,089 healthy testing participants using different subsets of EEG electrodes is 
shown in Table 3. Using all six electrodes (2 frontal, 2 central 2 occipital) provides the lowest prediction 
error (8.1 years) and the highest correlation with CA (0.81) (Kruskal-Wallis p-value < 0.01). If limited to 
recording EEG from one brain area only, the frontal or occipital electrode provide similar performance 
(p-value = 1), while being significantly better than the central electrode (p-value < 0.01). Therefore it is 
suggested to use frontal EEG electrodes, if required to use less EEG electrodes. 
Table 3. Brain age using subsets of EEG electrodes in healthy testing participants 
Electrode Mean absolute 
deviation (years) 
Pearson’s correlation 
Frontal (F3 and F4) 10.1 0.78 
Central (C3 and C4) 12.5 0.76 
Occipital (O1 and O2) 10.2 0.75 
All electrodes 8.1 0.81 
 
Longitudinal Reliability of the Brain Age Model 
 
To assess the longitudinal reliability of the brain age model, we use a subset of the SHHS dataset where 
each individual underwent two study visits, referred as SHHS1 and SHHS2 (1,760 adults, for a total of 
3,520 nights of EEG). The average time difference between the two visits is 5.2 years (SD 0.5 year) (Table 
2). We train the model in two ways. First, we train the model on 935 participants with paired EEGs 
(1,870 EEGs) from both visits and test the held out 825 participants with paired EEGs (1,650 EEGs) in 
both visits. The testing results are shown in Figure 3A and 3B. The MAD is 8.5 years on SHHS1 and 7.7 
years on SHHS2, and 8.1 years overall all. The Pearson’s correlation is 0.63 (95% CI 0.59 – 0.67) on 
SHHS1 and 0.66 (95% CI 0.62 – 0.70) on SHHS2. The average difference in predicted BA between the two 
visits (BA2 – BA1) is 5.5 years (SD 8.9 years) (Figure 3C). A t-test reveals no significant difference 
between BA2 – BA1 and CA2- CA1 (p-value = 0.3). 
Second, we train the model on the 2,432 EEGs from the healthy participants in MGH dataset using the 
C3-M2 and C4-M1 only (to be consistent with the SHHS dataset), and then predict BA on the 3,520 
paired EEGs in SHHS as the testing set. The results on the testing set are shown in Figure 3D and 3E. The 
MAD is 8.8 years on SHHS1 and 9.2 years on SHHS2. The Pearson’s correlation is 0.61 (95% CI 0.57 – 
0.64) on SHHS1 and 0.56 (95% CI 0.52 – 0.60) on SHHS2. The average difference in predicted BA 
between the two visits (BA2 – BA1) is 4.3 years (SD 10.3 years) (Figure 3F). A t-test reveals a significant 
difference between BA2 – BA1 and CA2- CA1 (p-value < 0.01). 
The results indicate that the model is able to accurately track the 5-years of aging elapsed between 
study visits at the population level when trained on part of SHHS and tested on the other part. When 
trained on MGH and tested on SHHS the model shows good generalization for age 40 to 70. The 
performance is modestly reduced as limited by having two central EEG electrodes in SHHS dataset 
instead of six in MGH dataset. 
 
Figure 3. (A and B) CA vs. BA from the 1,650 testing EEGs in SHHS when trained on the other part of 
SHHS. (D and E) CA vs. BA from the 3,520 testing EEGs in SHHS when trained on the healthy participants 
in MGH dataset. (C and F) Histogram of BA differences between two SHHS visits, showing tracking of age 
at the population level. The dashed red line is the Gaussian fit to the histogram. 
 
Correlation between Covariates and DA (BA – CA) 
 
We collect various covariates from the MGH dataset, including sleep macro-structure (i.e. sleep stages), 
the Epworth Sleepiness Scale, and measures of sleep disruptions and obtain the Spearman's correlation 
with the deviation of EEG-based brain age from CA (DA = BA - CA). For the healthy participants, the 
covariates with statistically significant Spearman’s correlation are shown in ascending order in Table 4. 
The full list of all covariates is shown in Table S4 in the supplementary material. The amount of deep 
sleep shows the most negative correlation with DA, although being weak. Wake time after sleep onset 
also shows weak but significant positive correlation with DA. 
The weak correlations indicate that DA is relatively independent from these covariates, such as apnea-
hypopnea index (AHI). Therefore DA can be interpreted as a relatively orthogonal metric for measuring 
sleep and brain health. In other words, DA is robust in participants with different characteristics. As an 
example, a scatter plot between AHI and CA/BA/DA shown in Figure S3 in the supplementary material 
reveals an correlation between AHI and CA/BA, not but DA, since it is canceled by taking the difference. 
Table 4. Covariates that have significant correlation with DA (BA-CA) 
Covariate Spearman's correlation 
N3 time -0.12 
N3 percentage -0.097 
Sleep efficiency -0.075 
Total sleep time -0.065 
N2 time -0.058 
Respiratory Disturbance Index 0.044 
N1 percentage 0.054 
Wake Time After Sleep Onset 0.078 
 
Correlation between Disease / Medication and DA (BA – CA) 
 
We next show DA in different health conditions. In Section Material and Methods we have described the 
criteria of being considered as having neurological or psychiatric diseases (Table S1), which are 
hypothesized to have older BA than CA. This hypothesis is verified as shown in Figure 4A. The DA for 
healthy group (2,432 participants) is around 0 year, while the DA for the group with neurological or 
psychiatric diseases (189 participants) increases up to 5 years with a significant difference (t-test p-value 
< 0.01). Therefore on a population level, the participants with neurological or psychiatric diseases have 
an average 5 years older brain age than their chronological age. Further, in the healthy group, the MAD 
is 8.1 years and correlation between CA and BA is 0.81; in the group with neurological or psychiatric 
diseases, the MAD is larger at 10.6 years and correlation smaller at 0.70, both of which are significant (p-
value < 0.01). 
Despite grouping participants based on their diagnosis of diseases, it is also worthy looking at how the 
medication affects DA. The MGH database includes self-reported types of medications in each of the 14 
gross categories prescribed at the time of EEG recording. The exact type or the dose is currently not 
provided as limited by the dataset. We search participants for all possible combinations of taking 1 to 4 
categories of medications. For each combination of medication categories, we apply a t-test to compare 
the DA of two groups: participants not taking any of the medications in this combination vs. participants 
taking all medications in this combination only (not taking others). Groups with less than 20 participants 
are excluded from the analysis to ensure statistical validity. The medication categories that have 
significantly different DA between the groups (t-test p-value < 0.05) are listed in Table 5. 
 
Table 5. DA (BA - CA) under different medication categories that is significant 
Medication Category 
DA without 
medications: 
mean (std) in years 
DA with 
medications: 
mean (std) in years 
#participant 
without 
medication
s 
#participant 
with 
medication
s 
Diabetic + Hypertension -0.49 (9.7) 3.8 (9.7) 1671 21 
Hypertension + Systemic -0.68 (9.6) 1.2 (10.2) 951 331 
 We hypothesize that participants with diabetics and hypertension tend to have older BA than CA. As 
shown in Figure 4B, participants taking medications for diabetics and hypertensions have significantly 
larger DA compared to those who are not taking these medications (p-value < 0.05). Comparison to the 
age norm reveals that the reason is that these participants tend to have more continual theta power 
during N1 and N2 stages. For benzodiazepine medications, the model gives younger brain age because 
of the they promotes the spindles which appears to be younger from the model point of view; similarly 
for opiate medications, the model also gives young brain age because they slows down EEG and hence 
more delta power and appears to be younger from the model point of view. 
 
Figure 4. (A) Histograms of DAs for participants with (red) and without (blue) neurological or psychiatric 
diseases defined in Table S1. The dashed lines show the Gaussian fit to these distributions. The 
difference in the mean value in the two groups is 5.1 years. (B) Histograms of DAs for participants taking 
(red) and not taking (blue) medications for diabetics and hypertension. The different in the mean value 
in the two groups is 4.3 years. 
 
Age Norm based on Sleep EEG Features 
 
The parametric formulation of our brain age model allows studying individual differences at the level of 
EEG features, as contrast to nonparametric models such as Gaussian process regression. To do this, we 
first derive the “age norm”, i.e. typical EEG feature values at different CAs with matched BAs. 
Specifically, the age norm of age x is obtained by averaging the z-transformed EEG features from all 
healthy participants who have both CA and BA within [x-5, x+5] years, as shown in Figure 5. 
 Figure 5. The age norm represented as a heat map. The features are ranked based on their correlation 
with CA. Panel A shows the age norm, i.e. average z-transformed EEG features. Panel B shows the 
standard deviation of the age norm. 
The age norm suggests that when following a normal aging process, the features with most negative 
correlation with age is delta band (< 4Hz) power in N3 stage in occipital and central areas; and the 
features with most positive correlation with age is theta band (4 – 8Hz) power in N1 stage in frontal, 
occipital and central areas (Table S5). 
Using this feature age norm, we can examine the reasons of the deviation from CA for the exemplar 
participants in Figure 6 instead of visual inspection of the spectrograms. This is a 29-year-old female 
accumulatively diagnosed as diabetes mellitus, obesity, smoker, cerebrovascular accident, congestive 
heart failure and acute renal failure not later than 1 year after the PSG recording. Her brain age is as 
high as 63-year-old. When compared to the age norm, her sleep EEG exhibits (1) more theta band bursts 
compared to the normal REM spectrum which has low theta band activity; (2) less delta to theta ratio 
during deep sleep; and (3) less theta and alpha band bursts, i.e. more continual theta and alpha, during 
N2 stage. Other examples are shown in Figure S4 – S6 in the supplementary material. 
 
Figure 6. A 29-year-old female accumulatively diagnosed as diabetes mellitus, obesity, smoker, 
cerebrovascular accident, congestive heart failure and acute renal failure not later than 1 year after the 
PSG recording with higher brain age than chronological age. The blue circle in the top left panel indicates 
this participant. The top right panel shows the hypnogram and EEG spectrogram from frontal (F), central 
(C) and occipital (O) channels. The bottom panel shows the top 5 features that, compared to age norm, 
contribute most positive net effect to the older brain age. The numbers in the parentheses indicates the 
range of age norm +/-2 standard deviation. 
 
Discussion 
Our study is distinguished by the use of large datasets: 2,621 sleep EEGs from the MGH Sleep Lab, and 
3,520 sleep EEGs from the SHHS dataset (Dean et al., 2016; Quan et al., 1997; Redline et al., 1998). The 
number of EEGs involved in this study is large among relevant “brain age” studies (Cole and Franke, 
2017). The large size of the datasets helps to ensure the statistical power as well as less selection bias. A 
large training set helps ensure that the trained model is not overfit to the particular dataset, improving 
the ability to generalize when applied beyond the training set. A large testing set allows accurate 
statistical measurement of how accurately the model predicts brain age. 
We use a parametric linear model, which allows easier interpretation by looking at each EEG feature and 
comparing to the age norm for each feature explicitly. In contrast, nonparametric or semi-parametric 
models such as kernel methods and Gaussian process models (Franke et al., 2010) estimate age 
essentially based on the similarity to the training examples, where the contribution of each feature is 
involved implicitly. An example of interpretability is demonstrated in Figure 6. A notable change in this 
example is the continual and spreading wide band oscillations. The continual theta power is consistent 
with prior literature on diabetic encephalopathy, where deficits in glucose metabolism lead to impaired 
functional connectivity (Baskaran et al., 2013; Franke et al., 2013; Sima, 2010). 
The deviations of EEG-based BA from CA might arise from multiple sources. These can be divided into 
technical and physiological factors. Technical factors include (1) EEG artifacts not removed by 
preprocessing; (2) constraints of the current model, which assumes brain age is a linear combination of 
sleep EEG features averaged separately for each sleep stage over the night; (3) imputation of missing 
sleep stages (Figure S2); and (4) first night effect, where the participants is not used to the sleep lab 
environment. Neurophysiological factors, our central interest, might arise from (1) night-to-night 
variability; (2) underlying diagnosed or undiagnosed neurological or psychiatric diseases; (3) general 
medical health, including diabetes and small vessel cerebrovascular disease; (4) there are substantial 
genetically-determined stable inter-individual differences in the EEG; (5) exposure to environmental 
insults. Further studies are needed to clarify the relative contributions of the various types of 
neurophysiological factors, and to measure the association between EEG-based brain age and various 
outcomes, such as cognitive performance (Steffener et al., 2016), intelligence (Ujma et al., 2017) and 
survival (Cole et al., 2017). The deviations suggest that there are unobserved factors, such as diet, 
exercise and diseases, to further explain the variance. On the other hand, it raises important questions 
that whether intervention on these factors can change sleep EEG, hence achieving a healthier brain 
aging process. 
It is possible to come up with brain age using multiple modalities, such as EEG, MRI (Cole and Franke, 
2017), actigraph, genetic and molecular (Horvath, 2013) biomarkers, which achieves more accurate 
prediction of brain function and disease risks. Combining features from different modalities help to 
reduce unobserved variance compared to using single modality. An age norm could also be derived 
based on multimodal features that have matched chronological age and brain age, thus providing more 
insights about the aging process. On the other hand, multimodal model sets a higher burden for easy 
usage or home-based devices since there are more signals to record. Another way to improve 
performance could be having multiple models for different demographic covariates, such as sex and 
race. 
There are some important limitations of our study. (1) The current dataset does not support the study of 
night-to-night variability of brain age as well as how it is affected by behaviors. Future studies should 
measure night-to-night variability, and the degree to which night-to-night differences are found to 
represent random noise vs. meaningful variation of brain function (e.g. due to differences in sleep 
quality and/or timing). An important  future assessment needs to be longitudinal studies with individual 
follow-up at multiple time points. (2) We only include ages 18 to 80. The distribution of ages in the 
dataset is not uniform, where participants in middle age are the most, and participants in young or old 
age are relatively fewer. This could lead to a systematic bias where old and pathological participants 
cannot have a much older brain age since the training set does not contain it. (3) Our model is limited by 
its linear structure. Advanced algorithms such as convolutional neural networks, trained end-to-end 
from raw EEG data rather than on hand-engineered physiologically-based features as in our model, 
might be able to predict age more accurately (Biswal et al., 2017; Cole et al., 2016). In addition, whereas 
we average features within the same sleep stage, representations learned by recurrent neural network 
models might provide a more powerful summary of the overnight EEG that utilizes more information 
(e.g. fragmentation of sleep stages) and more accurately reflects brain age. 
Conclusions 
Using a machine learning model, the brain age can be inferred from the pattern of brain activity during 
sleep. Specific diseases and medications, which make the participant deviate from normal aging process, 
can be reflected from the change in brain age. Using participants with matched chronological age and 
brain age, an age norm can be developed to provide a direct interpretation of the deviation in aging in 
terms of EEG features. In summary, the brain age serves as a potential biomarker which sets the stage 
for EEG-based studies of brain health. 
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